Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial
Laura S Farach,Melissa A Richard,Aynara C Wulsin,Elizabeth M Bebin,Darcy A Krueger,Mustafa Sahin,Brenda E Porter,Tarrant O McPherson,Jurriaan M Peters,Sarah O'Kelley,Katherine S Taub,Rajsekar Rajaraman,Stephanie C Randle,William M McClintock,Mary Kay Koenig,Michael D Frost,Klaus Werner,Danielle A Nolan,Michael Wong,Gary Cutter,Hope Northrup,Kit Sing Au,PREVeNT Study Group,E Martina Bebin,Darcy Krueger,Robert Flamini,Robert C Sergott,Tarrant McPherson,Kalyani Peri,Jessica Krefting,Brenda Porter,Katherine Taub,Brian Litt,Joyce Wu,Denise Lagory,Bruce Korf,Ludwig Messiaen,Fred Biasini,Anna Byars,Steven L Roberds,Gabrielle Rushing,Molly Griffith,Peter Davis,Ellen Hansen,Emine Arcasoy,Jennifer Phillips,Rayann Solidum,Amanda Gulsrud,Natalie Solis,Stephanie Randle,Kristina Patrick,Jacqueline Lee-Eng,Mike D Frost,Janet Branson,Sarah Ellis,Desiree White,Olga Novak,Ashley Fasciola,Jill Lorenzi,Marcus Layer,Allison Thomas,Emily Chanbers,Madison Berl,Nancy Elling,Bergen Kassoff,Kinaya Hardie,Danielle Nolan,Angela DeBastos,Christine Batchelder,Mary Kay Koening,Kit Su Au,Deborah Pearson,Rosleen Mansour,Laura Farach,Elida Salazar
DOI: https://doi.org/10.1016/j.pediatrneurol.2024.06.012
Abstract:Background: Children with tuberous sclerosis complex (TSC) are at high risk for drug-resistant epilepsy (DRE). The ability to stratify those at highest risk for DRE is important for counseling and prompt, aggressive management, necessary to optimize neurocognitive outcomes. Using the extensively phenotyped PREVeNT cohort, we aimed to characterize whether the TSC genotype was associated with DRE. Methods: The study group (N = 70) comprised participants with TSC enrolled at age less than or equal to six months with detailed epilepsy and other phenotypic and genotypic data, prospectively collected as part of the PREVeNT trial. Genotype-phenotype correlations of DRE, time to first abnormal electroencephalography, and time to epilepsy onset were compared using Fisher exact test and regression models. Results: Presence of a TSC2 pathogenic variant was significantly associated with DRE, compared with TSC1 and participants with no pathogenic mutation identified. In fact, all participants with DRE had a TSC2 pathogenic variant. Furthermore, TSC2 variants expected to result in no protein product were associated with higher risk for DRE. Finally, TSC1 pathogenic variants were associated with later-onset epilepsy, on average 21.2 months later than those with other genotypes. Conclusions: Using a comprehensively phenotyped cohort followed from infancy, this study is the first to delineate genotype-phenotype correlations for epilepsy severity and onset in children with TSC. Patients with TSC2 pathogenic variants, especially TSC2 pathogenic variants predicted to result in lack of TSC2 protein, are at highest risk for DRE, and are likely to have earlier epilepsy onset than those with TSC1. Clinically, these insights can inform counseling, surveillance, and management.